700 Main Street
11 articles about EnBiotix
The problem Kinaset is trying to solve is that over time, patients receiving asthma therapies – typically inhaled corticosteroids plus bronchodilators – become steroid-refractory.
Polyphor AG and EnBiotix Inc. announced that EnBiotix has completed a convertible debenture raise of USD 11 million to finance its future operations.
EnBiotix, Inc., a rare disease company currently focused on chronic respiratory disorders, announced the closing of an $11M pre-merger, convertible note round of financing comprised of Vectura Group plc, the Cystic Fibrosis Foundation and Sanford Biosciences LLC.
Polyphor and EnBiotix Announce Dosing of First Patient in a First-in-Human Clinical Trial of Inhaled Murepavadin
Polyphor AG and EnBiotix Inc. announced that the first subjects have been dosed in the first-in-human Phase I trial of a novel-class antibiotic murepavadin, delivered via the oral inhalation route.
Polyphor and EnBiotix Announce Signing of Merger Agreement and Sale of Inhaled Murepavadin to EnBiotix
Polyphor and EnBiotix Inc. announced that the companies have signed a merger agreement pursuant to which Polyphor acquires all of the outstanding capital stock of EnBiotix in exchange for shares of Polyphor common stock.
EnBiotix Reports Publication Highlighting Anti-Persister Agent Targeting Antibiotic-Tolerant Infections In Antimicrobial Agents And Chemotherapy
EnBiotix Receives Grand Challenges Explorations Grant For Groundbreaking Research In Global Health And Development